A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS
about
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionThe good and evil of complement activation in HIV-1 infectionCellular proteins associated with the interior and exterior of vesicular stomatitis virus virionsProvirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Complement and HIV-I infection/HIV-associated neurocognitive disorders.HIV-1 coinfection profoundly alters intrahepatic chemokine but not inflammatory cytokine profiles in HCV-infected subjects.Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59.Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.A simple PCR-based method for the rapid genotyping of inherited fifth complement component (C5)-deficient mice.CD59 incorporation protects hepatitis C virus against complement-mediated destruction.Optimized method for computing (18)O/(16)O ratios of differentially stable-isotope labeled peptides in the context of postdigestion (18)O exchange/labeling.Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.Gene duplication and phylogeography of North American members of the Hart Park serogroup of avian rhabdoviruses.Rapid degradation of the complement regulator, CD59, by a novel inhibitorProtein engineering to target complement evasion in cancer.Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system.Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.Effector mechanisms of humoral immunity to porcine reproductive and respiratory syndrome virus.rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.Glycosylphosphatidylinositol Anchor Deficiency Attenuates the Production of Infectious HIV-1 and Renders Virions Sensitive to Complement Attack.Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.CD59 association with infectious bronchitis virus particles protects against antibody-dependent complement-mediated lysis.
P2860
Q21245045-7F9342BB-3B92-40A0-A389-39E4233BE8B8Q28275986-0EAC2FFD-B40E-49D9-B245-DAC7FBF13BBCQ34020589-08EC719B-22BA-4BD1-BDFB-ED9CD8F01F9FQ34218827-69D5F001-4E80-4550-BC27-2A7913F5C792Q34610122-CD02C1AA-FBF6-472C-8DC0-B419E0DFB028Q35091404-7DFDCF4E-EDDF-4DC0-9D3E-C646FAF02F0EQ35897605-201AA46A-263B-4FC3-9774-03FF0E91CCCBQ35973601-B2BAF42A-A47A-44EC-897C-A60544A0C6FFQ35991991-0012A0C4-FA83-4F43-90C3-497904788B3BQ36158037-1E3A9878-F1AE-489B-BD84-E4BAFB7D4DE4Q36343288-0600B7B5-6A93-42EB-91F5-1A414BBBC16CQ36754719-083EA221-FCC3-44DB-B659-6BF384C7BC21Q37415138-05CDB7C6-F91A-44BB-A96D-C2A0162A07DCQ37727650-5CAC2B52-578F-41A7-A235-3F0F0D3C9F87Q38163242-6DDAF0C4-5F4F-4EA0-8647-88283A387983Q38738490-16C72E10-E1FB-4D1A-A3C6-B824194F135BQ39024745-1C67F56D-849B-40AD-A2C5-C8B1FAF1BE2BQ39245066-C97794EA-B165-4B1C-B3FA-E864BFB288A6Q39473725-E798A553-58AA-40CF-89B5-A10A3B36BB9DQ40657302-E0CCF267-089E-4F82-B4FD-6A2653FB50BEQ41556124-6BFED434-5894-4EDA-963E-E91618FFEE41Q43084911-99191C41-ECF1-4500-9B29-6284E7E5A2D4Q45325724-8BC2FDD6-D334-4E50-AB72-B0D04757AD9C
P2860
A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@ast
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@en
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@nl
type
label
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@ast
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@en
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@nl
prefLabel
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@ast
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@en
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@nl
P2093
P2860
P356
P1476
A high-affinity inhibitor of h ...... ns for treatment of HIV-1/AIDS
@en
P2093
Bruce Shiramizu
Cecilia Shikuma
Daniel Byrd
Jose A Halperin
Ningjie Hu
Tohti Amet
Xuebin Qin
P2860
P304
P356
10.4049/JIMMUNOL.0902278
P407
P577
2009-12-02T00:00:00Z